Earnings

Lilly sales fall, drugmaker to keep rep count low

Lilly sales fall, drugmaker to keep rep count low

By

Cymbalta and Evista patent losses drove down sales, but Lilly said it does not plan to replenish the sales force it thinned in anticipation of the decline.

GSK restructures, as respiratory disappoints

GSK restructures, as respiratory disappoints

By

GlaxoSmithKline's third-quarter sales fell 10% for the quarter, compared to last year, and new Ellipta products failed to cushion the 24% drop in US Advair sales.

Hep. C medication boosts J&J earnings

Hep. C medication boosts J&J earnings

By

Hepatitis C medication Olysio contributed to the the 18% bump in Johnson & Johnson's third-quarter sales, but Gilead's new drug may diminish J&J's potential.

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi tightens PCSK9 race, exceeds Q2 expectations

By

Sanofi and partner Regeneron attached a $67.5-million priority review voucher to their experimental cholesterol drug alirocumab, making for a tighter race with Amgen.

Amgen Q2 sales rise, company to lay off up to 2,900

Amgen Q2 sales rise, company to lay off up to 2,900

By

The majority of the layoffs will be in the US.

Pfizer Q2 sales slip, but still beat expectations

Pfizer Q2 sales slip, but still beat expectations

By

Patent losses and lost co-promotion agreements put a dent in sales.

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

By

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.

Gilead, Merck HCV marketing battle may be on horizon

Gilead, Merck HCV marketing battle may be on horizon

By

Disclosed in its earnings report yesterday, Gilead may have a card up its sleeve to counter Merck's experimental hep. C combo regimen.

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

By

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.

GSK second-quarter sales disappoint

GSK second-quarter sales disappoint

By

Executives urge analysts to focus on the company's long-term potential.

J&J logs $19.5B in Q2 sales

J&J logs $19.5B in Q2 sales

By

Hepatitis C medication Olysio was a star, but the company cautions competition is coming.

Aegerion shows rare disease not slam dunk

Aegerion shows rare disease not slam dunk

By

Analyst reaction to this week's quarterly news reflected a need to woo investors, adding to some negative carryover from the previous year.

Pfizer posts weak Q1 sales, stands by AZ offer

Pfizer posts weak Q1 sales, stands by AZ offer

By

CEO Ian Read told investors Monday that an AZ merger would benefit Astra shareholders and add oomph to its marketing potential. Another exec said he could "envision" filing palbociclib this year, but made no promises.

GSK's first-quarter sales slide

GSK's first-quarter sales slide

By

US sales fell 10%, and corruption allegations in China ate into emerging-market sales.

Merck Q1 sales fall, but diabetes rises

Merck Q1 sales fall, but diabetes rises

By

Sales of its big diabetes franchise rose 3% vs. the same period last year, while drops in Singulair and Nasonex revenue marked the quarter. The company is slated to reveal pipeline progress next week.

Lilly Q1 sales dip

Lilly Q1 sales dip

By

US sales fell 34% during the quarter, largely due to lower demand and lower prices for off-patent Cymbalta and Evista.

Recalls dent Stryker Q1 earnings

Sales rose 5% compared to the same period last year.

Roche wraps quarter with two fewer pipeline medications

Roche wraps quarter with two fewer pipeline medications

By

Roche also announced first-quarter sales shrank 1%.

LOEs continue to buffet AstraZeneca

LOEs continue to buffet AstraZeneca

By

The drugmaker expects to return emerge from 2016 with over 5,000 fewer employees and return to growth mode in 2017.

Sanofi muddles through 2013

Sanofi muddles through 2013

By

Constant exchange rates provide a positive framework for quarterly and year-end totals, whereas straight percentages indicate lower sales.

Merck: 2014 is the year of the rebuild

Merck: 2014 is the year of the rebuild

By

The company expects to return to growth in 2015 as it focuses on immunotherapy collaborations.

Lilly says 2014 will not be "trough year"

Lilly says 2014 will not be "trough year"

By

Higher prices helped insulate Q4 and annual sales, which fell and rose 2%, respectively. Lilly said its insulin glargine biosimilar will go nowhere if it is not substantially different from the competition.

Watershed year ups expectations for Biogen

Watershed year ups expectations for Biogen

By

Taken to new heights on the launch of MS blockbuster Tecfidera, the drug maker has raised its 2014 forecast.

Novartis pharma sales held steady in 2013

Novartis pharma sales held steady in 2013

By

Generics took a $2.2-billion bite out of sales, but growth products like Gilenya helped to minimize the impact.

Pfizer's Q4 fails to wow, but palbo' news may

Pfizer's Q4 fails to wow, but palbo' news may

By

The company said it may use Phase II data of a breast cancer drug for FDA review, part of an earnings presentation that also included its perspective on what a pre-2017 breakup would take.

Analysts put weight on BMS in oncology

Analysts put weight on BMS in oncology

By

Friday's no-nivolumab news event disappointed some, but analysts generally rooted for BMS, which saw year-end sales fall 7%, because of anticipated immuno-oncology success.

Vivus slims down in wake of sluggish sales

Vivus slims down in wake of sluggish sales

By

The drugmaker says 20 jobs, or 17% of its workforce, will be gone by the end of the year.

Novo sales rise, company braces for change

Novo sales rise, company braces for change

By

The drug maker's vision for 2014: fighting to keep Victoza top-of-mind with a US field force of around 3,000.

AstraZeneca reveals new CFO and lagging Q3 results

AstraZeneca reveals new CFO and lagging Q3 results

By

The company's latest numbers show generics continue to pummel sales. Former GSK-er Marc Dunoyer replaces departing CFO Simon Lowth.

WebMD is bringing former advertisers back on board

WebMD is bringing former advertisers back on board

By

The company says it recaptured some former advertisers and that third-quarter traffic is up compared with last year.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.